SAREUM REPORT POSITIVE TESTS ON CANCER DRUGS

Sareum, the specialist cancer drug discovery business, has announced positive results from pre-clinical in-vivo efficacy studies from their joint research collaboration with Cancer Research Technology and The Institute of Cancer Research.

A recent colon cancer pre-clinical model study carried out demonstrates that the combination of a collaboration Chk1 inhibitor, dosed via the oral route, in combination with a chemotherapeutic, gemcitabine, demonstrates a greater than two-fold reduction in cancer growth rate compared to treatment with the same dose of gemcitabine without the Chk1 inhibitor.

Sareum's CEO, Dr Tim Mitchell, commented: "These are exciting advances, demonstrating efficacy of our Chk1 compounds in several cancer models. Studies on additional models are on-going. We believe the results from the recently conducted studies will significantly enhance the licencing package and assist the collaboration in selecting the best compound for development into a clinical trials candidate".